Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ Origin: Appendix 5 \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$

Name o	of entity		
UCW	Limited		
ABN			
85 108	962 152		
We (tl	We (the entity) give ASX the following information.		
	1 - All issues set complete the relevant sections (attach	sheets if there is not enough space).	
1	⁺ Class of ⁺ securities issued or to be issued	Performance Rights (zero-exercise price options, issued under the Company's Employee Option Plan (EOP))	

Number of *securities issued or to be issued (if known) or maximum number which may be issued 1,600,000, being:

- 800,000 to Adam Davis (CEO), as approved at the AGM on 9 November 2018; and
- 800,000 to Lyndon Catzel (CFO and Company Secretary)

⁺ See chapter 19 for defined terms.

Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

The Performance Rights have the following principal terms:

- (i) Exercise price: Nil
- (ii) Vesting and performance conditions:
 - i. Three (3) years of continuous employment or office with the Company from the date of issue; and
 - ii. At the above date (being three years from the date of issue), the UCW share price (90-day VWAP of shares traded on the ASX) must be no less than \$0.30
- (iii) Expiry: 1 month after the vesting date

Further details can be found in the Notice of Meeting provided to ASX on 8 October 2018.

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No. Performance Rights are not quoted securities and do not rank equally with ordinary shares. Performance Rights do not confer a right to vote, a right to receive dividends or any other rights of a shareholder.

Ordinary shares issued on exercise of the Performance Rights will rank equally in all respects with the existing ordinary shares of the Company.

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

5	Issue price or consideration	Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The Performance Rights constitute part of Mr Davis' and Mr Catzel's respective total remuneration packages.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	09 November 2018
6с	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of *securities issued under an exception in rule 7.2	1,600,000
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A

⁺ See chapter 19 for defined terms.

6h	If +se	curities v	vere	issue	d un	ıder
	rule	7.1A	fo	r r	ion-c	ash
	consid	deration,	sta	ate c	late	on
	which	ı valuatio	n of	consi	derat	tion
	was	released	to	ASX	Mai	rket
	Anno	uncemen	ts			

N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7.1 - 7,023,187	
7.1A - 11,015,458	

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

22 November 2018		

8 Number and *class of all *securities quoted on ASX (*including* the *securities in section 2 if applicable)

Number	+Class
110,154,583	Fully paid ordinary shares

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
400,000	Unlisted options, each exercisable at \$0.29620 per option expiring on 31 July 2021. The options vest on 31 July 2019.
400,000	Unlisted options, each exercisable at \$0.39620 per option expiring on 31 July 2021. The options vest on 31 July 2019.
1,600,000	Unlisted Performance Rights, vesting on 22 November 2021, subject to meeting the performance conditions. The Performance Rights expire no later than 22 December 2021.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			
N/A			

⁺ See chapter 19 for defined terms.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
	cherements.	
	D 1: C 1 : 1:1	27/4
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

⁺ See chapter 19 for defined terms.

	Appendix 3B New issue announcement			
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A		
		F		
32	+Issue date	N/A		
	3 - Quotation of securitie rd only complete this section if you are ap Type of *securities (tick one)			
(a)	*Securities described in Part	1		
(b)		nd of the escrowed period, partly paid securities that become fully paid, on restriction ends, securities issued on expiry or conversion of convertible		

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)				
38	Number of *securities for which *quotation is sought			
39	⁺ Class of ⁺ securities for which quotation is sought			
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment			
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another +security, clearly identify that other +security)			
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	Number	+Class	

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 22 November 2018

(Director/Company secretary)

Print name: Lyndon Catzel

== == == ==

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	74,775,231			
Add the following:				
Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2	25,000,000			
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 	10,379,352			
 Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 	Nil			
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 				
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil			
"A"	110,154,583			

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"				
"B"	0.15			
	[Note: this value cannot be changed]			
Multiply "A" by 0.15	16,523,187			
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used				
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:				
Under an exception in rule 7.2	Up to a maximum of 9,500,000 fully paid ordinary shares, determined in accordance with the Share Sale Agreement entered into			
Under rule 7.1A				
 With security holder approval under rule 7.1 or rule 7.4 	on 4 July 2018 with the vendors of IKON Institute (refer previous ASX Announcements). The shares will be issued at the 20-day volume weighted average			
Note:	at the 20-day volume weighted average price at the time of payment (expected to be September 2019).			
 This applies to equity securities, unless specifically excluded – not just ordinary securities 				
Include here (if applicable) the securities the subject of the Appendix				
3B to which this form is annexed				
• It may be useful to set out issues of securities on different dates as separate				
line items				
"C"	9,500,000			
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1				
"A" x 0.15				
Note: number must be same as shown in Step 2	16,523,187			
Subtract "C"				
Note: number must be same as shown in Step 3	9,500,000			
<i>Total</i> ["A" x 0.15] – "C"	7,023,187			
	[Note: this is the remaining placement capacity under rule 7.1]			

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
"A"				
Note: number must be same as shown in Step 1 of Part 1	110,154,583			
Step 2: Calculate 10% of "A"				
"D"	0.10			
	Note: this value cannot be changed			
Multiply "A" by 0.10	11,015,458			
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used				
 Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed 	Nil			
 Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	Nil			

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A				
"A" x 0.10				
Note: number must be same as shown in Step 2	11,015,458			
Subtract "E"				
Note: number must be same as shown in Step 3	Nil			
Total ["A" x 0.10] – "E"	11,015,458			
	Note: this is the remaining placement capacity under rule 7.1A			

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.